Market Cap.: ₹ 67,546.07 Cr.
Current Price: ₹ 1,496.25
Book Value: ₹ 277.53
Stock P/E: 23.94
Dividend Yield: 0.50%
Face Value: ₹ 2.00
Net profit: 2,270.69
Profit growth: 20%
this year result seems to be good
profit growth seems to be good
Lupin Limited is a transnational pharmaceutical company based in Mumbai. It is the seventh-largest company by market capitalization; and the 10th-largest generic pharmaceutical company by revenue globally. Lupin is the fifth-largest generic pharmaceutical company in the US by prescription-led market share and 3rd largest Indian pharmaceutical company by revenue. It has the distinction of being the fastest growing generic pharmaceutical player in the US and Japan;, and is the 4th largest and the fastest growing generic pharmaceutical player in South Africa.
Seems like too much acquisition in medical pharma sector
Stock price is 1.5 times
Diversified field in pharma
country wise also spread all over world
although shareholder letter is not much informative about future prospects the annual report has all the required information
company growth is impressive
management seems capable
has maintained the growth old organization deep roots in many countries now.. expanding the business very fast ..
You can invest
Took lot of loan for acquisition
what if the acquired company in Japan and US do not perform as expected
Has done some costly acquisitions in Japan and US.. Gavis, Novel
Rakesh jhunjhunwala fav company
USFDA is a big hurdle for Indian Pharma companies
Final Verdict: Average Can buy but at lower price.
I am very new to value investing and this is me taking random notes just for myself. Please don’t base any of your decision on these write-ups. That will be foolish.